1
|
Effect of Different Anesthesia Methods on Emergence Agitation and Related Complications in Postoperative Patients with Osteosarcoma. JOURNAL OF HEALTHCARE ENGINEERING 2021; 2021:7120035. [PMID: 34950442 PMCID: PMC8692017 DOI: 10.1155/2021/7120035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 11/11/2021] [Accepted: 11/20/2021] [Indexed: 11/17/2022]
Abstract
Purpose To explore the effect of different anesthesia methods on emergence agitation (EA) and related complications in postoperative patients with osteosarcoma. Methods According to the order of admission, 115 patients requiring osteosarcoma surgery treated in our hospital from January 2018 to December 2020 were selected as the research object and randomly divided into the control group (n = 57, accepted the general anesthesia with tracheal intubation) and the experimental group (n = 58, accepted the combined spinal-epidural anesthesia) to compare their anesthesia effect, incidence rates of agitation and complications, and other indexes. Results In terms of the hemodynamic indexes (MAP, HR, and CVP values), both groups had lower ones at T1 than at T0, but the decline of the experimental group was generally lesser than that of the control group; at T2, no statistical difference was shown within the experimental group's indexes when comparing with those at T1, but the control group obtained a significant increase; at T3 and T4, both groups had their hemodynamic indexes increased, but such increase within the experimental group showed no statistical difference when comparing with those at T0, while the control group achieved obviously higher values at T4 than at T0 (before the anesthesia); and the between-group difference in the hemodynamic indexes at T1 and T4 was significant. Compared with the control group, the experimental group achieved better VAS scores and anesthesia indexes and lower incidence rates of EA and complications such as the hypoxemia, cardiovascular response, delayed recovery, and headache. In addition, the differences in the incidence rates of hypotension and cognitive dysfunction between the two groups were not statistically significant. Conclusion When comparing with tracheal intubation general anesthesia, the combined spinal-epidural anesthesia has a better effect in osteosarcoma surgery, with less hemodynamics influence on patients, reduced postoperative pain and stress reaction, and lowered incidence rates of postoperative EA and complications, which is worthy of wide application in clinical treatment.
Collapse
|
2
|
Jiang P, Yang X, Li Y, Chen J. miRNA-216 knockdown has effects to suppress osteosarcoma via stimulating PTEN. Food Sci Nutr 2020; 8:4708-4716. [PMID: 32994932 PMCID: PMC7500758 DOI: 10.1002/fsn3.1587] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 02/21/2020] [Indexed: 12/11/2022] Open
Abstract
The aim of this study is to explain the effects and mechanism of miRNA-216 in osteosarcoma. We firstly evaluated the PTEN expression in 30 pairs of tumor and adjacent tissues which were from the 30 osteosarcoma patients. In the following cell experiments, we measured the cell proliferation, cell cycle, cell invasion, and migration abilities of NC (normal control) group, BL (blank) group, siRNA (miRNA-216 inhibitor) group, and siRNA+PTEN inhibitor group. Furthermore, we measured the relative protein expression of difference groups by WB to explain the mechanism of miRNA-216 in osteosarcoma. The PTEN was confirmed the target gene of miRNA-216 by double luciferase target test. In conclusion, miRNA-216 was an oncogene in osteosarcoma. miRNA-216 knockdown had effects to suppress cancer cell proliferation, invasion and migration and improve cell apoptosis by keeping in G1 phase via PTEN.
Collapse
Affiliation(s)
- Ping Jiang
- Department of Orthopaedics Affiliated Hospital of North Sichuan Medical College Nanchong China
| | - Xin Yang
- Department of Orthopaedics Affiliated Hospital of North Sichuan Medical College Nanchong China
| | - Yuanli Li
- Department of Orthopaedics Affiliated Hospital of North Sichuan Medical College Nanchong China
| | - Juan Chen
- Department of Orthopaedics Affiliated Hospital of North Sichuan Medical College Nanchong China
| |
Collapse
|
3
|
Xu M, Wang Z, Yu XC, Lin JH, Hu YC. Guideline for Limb-Salvage Treatment of Osteosarcoma. Orthop Surg 2020; 12:1021-1029. [PMID: 32633103 PMCID: PMC7454155 DOI: 10.1111/os.12702] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 04/20/2020] [Indexed: 12/26/2022] Open
Abstract
Osteosarcoma is the most common primary malignant bone tumor, occurring mainly in children and adolescents, and the limbs are the main affected sites. At present, limb‐salvage treatment is considered as an effective basic standard treatment for osteosarcoma of the limb. China has a vast territory, but the development of technology is not balanced,which requires sufficient theoretical coverage, strong technical guidance and the application of limb‐salvage treatment guidelines to the treatment of osteosarcoma. Therefore, to standardize and promote the development of limb‐salvage surgery technology and improve the success rate of limb‐salvage treatment, this guide systematically introduces limb‐salvage techniques for the treatment of patients with limb osteosarcoma through definition of limb‐salvage treatment, surgical methods, efficacy evaluation, postoperative treatment and prevention of complications, rehabilitation guidance, and follow‐up advice.
Collapse
Affiliation(s)
- Ming Xu
- Department of Orthopedics, The 960th Hospital of PLA, Jinan, China
| | - Zhen Wang
- Department of Orthopedics, Xi-jing Hospital, Air Force Military Medical University, Xi'an, China
| | - Xiu-Chun Yu
- Department of Orthopedics, The 960th Hospital of PLA, Jinan, China
| | - Jian-Hua Lin
- Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
| | - Yong-Cheng Hu
- Department of Bone Oncology, Tianjin hospital, Tianjin, China
| |
Collapse
|
4
|
Li Y, Xu H, Shan H, Sun Y, Huang Z, Niu X. [Application of proximal tibial hemiprosthesis replacement and second-stage revision for proximal tibial osteosarcoma in three children]. ZHONGGUO XIU FU CHONG JIAN WAI KE ZA ZHI = ZHONGGUO XIUFU CHONGJIAN WAIKE ZAZHI = CHINESE JOURNAL OF REPARATIVE AND RECONSTRUCTIVE SURGERY 2019; 33:131-137. [PMID: 30739403 DOI: 10.7507/1002-1892.201810022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Objective To investigate the feasibility and effectiveness of proximal tibial hemiprosthesis replacement in the first stage and prosthesis revision in the second stage in reducing the risk of length discrepancy of limbs in children with proximal tibial osteosarcoma. Methods Between 2009 and 2013, 3 children with conventional osteosarcoma at the proximal tibia (stage ⅡB) were treated. There were 2 boys and 1 girl. They were 12, 13, and 13 years old, respectively. After 4 courses of preoperative chemotherapy, the proximal tumor segmental resection and proximal tibial hemiprosthesis replacement were performed. Then the patients underwent prosthetic revision in the second stage when they were 20, 17, and 17 years old, respectively. Results All patients successfully completed two stages of operations. The length discrepancy of lower limb after the second stage operation were 19, 7, and 21 mm, respectively. Three patients were followed up 13, 3, and 27 months after the second stage operation, and the lower extremities functions were satisfactory. The Musculoskeletal Tumor Society (MSTS) score was 26, 27, and 25, respectively. Conclusion The proximal tibial hemiprosthesis replacement in the first stage combined with prosthesis revision in the second stage for treating the proximal tibia osteosarcoma in children can keep the distal femur growth ability, reduce the length discreapancy of lower limb, and obtain satisfactory stability and good function.
Collapse
Affiliation(s)
- Yuan Li
- Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, 100035, P.R.China
| | - Hairong Xu
- Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, 100035, P.R.China
| | - Huachao Shan
- Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, 100035, P.R.China
| | - Yang Sun
- Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, 100035, P.R.China
| | - Zhen Huang
- Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, 100035, P.R.China
| | - Xiaohui Niu
- Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, 100035,
| |
Collapse
|
5
|
Deng ZP, Liu BY, Sun Y, Jin T, Li B, Ding Y, Niu XH. Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy. Chin Med J (Engl) 2018; 130:2215-2218. [PMID: 28875957 PMCID: PMC5598334 DOI: 10.4103/0366-6999.213960] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background: Limb-salvage surgery is the standard procedure for the treatment of appendicular osteosarcoma. Precise resection is the trend in limb-salvage surgery. The aim of this study was to evaluate a large series of cases to identify the histological relationship between the tumor and marrow and determine the intramedullary transition type and width from the tumor to normal marrow in patients with osteosarcoma after neoadjuvant chemotherapy. Methods: One hundred and six osteosarcoma specimens were evaluated. The tissue specimens were sectioned through the coronal axis by an electronic saw. The tissue was immersed in formalin solution for fixation and subsequently decalcified. The interface between the tumor and normal bone marrow was grossly determined and submitted for microscopic evaluation to detect the relationship between the tumor and bone marrow and identify the transition type and width. All histological slides were examined by experienced orthopedic pathologists. Results: Histologically, the interface between the tumor and normal bone marrow was classified into two patterns: “clear” and “infiltrated.” The clear pattern, characterized by a clear boundary between the tumor and marrow, was identified in sixty cases (56.6%). A subtype of the clear type, characterized by fibrous bands between the tumor and marrow, was found in 13 cases (12.3%). The infiltrated pattern, characterized by a boundary with tumor cell clusters embedded in the marrow, was found in 46 cases (43.4%). The infiltrating depth varied from 1 to 4 mm (mean, 2.6 ± 0.7 mm). No tumor cells were observed in the normal bone marrow areas next to the interface. Conclusions: The transition from osteosarcoma tissue to bone marrow after neoadjuvant chemotherapy can be divided into two histological patterns: clear and infiltrated. The greatest infiltration width was 4 mm from tumor to normal marrow in this study. This depth should be considered in the presurgical plan.
Collapse
Affiliation(s)
- Zhi-Ping Deng
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| | - Bao-Yue Liu
- Department of Pathology, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| | - Yang Sun
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| | - Tao Jin
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| | - Bin Li
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| | - Yi Ding
- Department of Pathology, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| | - Xiao-Hui Niu
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China
| |
Collapse
|
6
|
Meng Q, Dai M, Nie X, Zhang W, Xu X, Li J, Mu H, Liu X, Qin L, Zhu X, Yan J, Zheng M. MicroRNA-19 contributes to the malignant phenotypes of osteosarcoma in vitro by targeting Pax6. Tumour Biol 2018; 40:1010428317744704. [PMID: 29345189 DOI: 10.1177/1010428317744704] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
This study was conducted to detect the expression of miR-19 and Pax6 (Paired box protein 6) in human osteosarcoma cells and the effects on biological characteristics of osteosarcoma cells. Quantitative real-time polymerase chain reaction was used to detect the expression of Pax6 and miR-19 in normal human osteoblasts (hFOB 1.19) and osteosarcoma cell lines (U2OS, Saos-2, and MG-63). Results showed that miR-19 was significantly upregulated in osteosarcoma cell lines compared with that in hFOB 1.19 cells, while the expression of Pax6 messenger RNA was significantly downregulated. Pax6 was defined as the target gene of miR-19 which was validated by luciferase reporter gene analysis. Results indicated that miR-19 had an interaction with Pax6 3'-untranslated region. At the same time, the protein expression of Pax6 was significantly decreased in the MG-63 cells transfected with miR-19 mimic and was notably enhanced in osteosarcoma MG-63 cells transfected with miR-19 inhibitor. These data suggested that Pax6 was a target of miR-19 in osteosarcoma MG-63 cells. The effects of miR-19 on the biological behavior of MG-63 cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, and Transwell assay. Results showed that the downregulation of miR-19 inhibited cell viability, reduced the percentage of cells in S phase and the number of cells passing through the Transwell chamber, and increased the number of apoptotic cells. Western blot analysis showed that the inhibition of miR-19 significantly increased the expression of epithelial proteins (E-cadherin and β-catenin) and decreased the expression of mesenchymal protein (Vimentin), extracellular signal-regulated kinase, and phosphorylated extracellular signal-regulated kinase in MG-63 cells. MiR-19 inhibitor and Pax6 small interfering RNA were simultaneously transfected into MG-63 cells. Results from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, and Transwell assay demonstrated that the inhibition of Pax6 expression in MG-63 cells could reverse the cell biological effects induced by the inhibition of miR-19 expression. Based on these findings, it was suggested that miR-19, upregulated in osteosarcoma cells, negatively regulated the expression of Pax6, which can promote the malignant phenotypes of osteosarcoma cells via activation of the extracellular signal-regulated kinase signaling pathways. Therefore, miR-19/Pax6 may offer potential for use as a target for the treatment of osteosarcoma.
Collapse
Affiliation(s)
- Qingbing Meng
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Ming Dai
- 2 Department of Medical Laboratory, School of Public Health, Nantong University, Nantong, P.R. China
| | - Xuejun Nie
- 3 Department of Ultrasound, Affiliated Hospital of Nantong University, Nantong, P.R. China
| | - Wensheng Zhang
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Xingli Xu
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Jian Li
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Hongxin Mu
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Xiaolan Liu
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Ling Qin
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Xiaoqi Zhu
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Jun Yan
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| | - Minqian Zheng
- 1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China
| |
Collapse
|